Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ).
Shanghai Henlius Biotech, Inc. announced that shareholders approved an ordinary resolution at its fourth extraordinary general meeting of 2025, held in Shanghai on 31 December, with all directors in attendance and 16.38% of share capital represented. The resolution, supported by 100% of votes cast after major Fosun Pharma–related shareholders abstained, renews the Sinopharm Distribution Framework Agreement for 2025 and its annual caps, authorising directors to execute all necessary actions to implement the renewed distribution arrangement, which underpins Henlius’s commercial channel strategy and reinforces its partnership with a key pharmaceutical distributor in China.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a PRC-incorporated biopharmaceutical company listed in Hong Kong that focuses on the research, development, manufacturing and commercialization of biologic drugs, including biosimilars and innovative therapies, targeting domestic and international markets through both proprietary sales and distribution partnerships.
Average Trading Volume: 1,152,685
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.98B
See more insights into 2696 stock on TipRanks’ Stock Analysis page.